Reviva Pharmaceuticals (RVPH)
Develops brilaroxazine-led therapies for CNS, inflammatory, and cardiometabolic diseases.
Something off on this page? Send us feedback.
Reviva is a late-stage biotechnology company developing brilaroxazine for schizophrenia and other CNS-related indications, with RP1208 as an earlier pipeline asset. FDA feedback has put a second registrational phase 3 schizophrenia trial on the critical path before a possible NDA.
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on internally discovered drug candidates for central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline is led by brilaroxazine, also known as RP5063, an oral dopamine-serotonin modulator being developed primarily for acute and maintenance schizophrenia.
Reviva also lists potential neuropsychiatric extensions, respiratory indications such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis, topical psoriasis work, and RP1208 for depression and obesity. In March 2026, the company said FDA feedback called for a second registrational phase 3 trial before a possible brilaroxazine NDA, and it planned RECOVER-2 activities for 2026. Reviva has no approved commercial product; its path depends on clinical execution, regulatory review, manufacturing readiness, patents, and access to additional capital.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $19.89T · Total debt $144.09B · Total assets $21.14T · Shareholders' equity $15.21T
- Revenue
- $0
- Operating income
- −$2.62T
- Net income
- −$2.45T
No dividends on record.
| Institutions | 0.06% | 7.7K shares | |
|---|---|---|---|
| 5 holders · as of Jun 30, 2026 | |||
| Strategic holders | 11.88% | 1.56M shares | |
| 2 holders · as of May 14, 2026 | |||
| Other | 88.06% | 11.55M shares | |
| remainder | |||
13.11M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Integrated Core Strategies (US) LLCStrategic | 6.06% | 793,952 | filed Mar 30, 2026 |
Barclays PLCStrategic | 5.82% | 763,579 | filed May 14, 2026 |
UBS Group AGInstitution | 5.69% | 746,095 | filed May 7, 2026 |
Emc Capital ManagementInstitution | 0.05% | 6,696 | as of Jun 30, 2026 |
TD Waterhouse Canada Inc.Institution | 0.00% | 625 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
Not reported.